
Exagen Inc (XGN) Stock Forecast & Price Target
Exagen Inc (XGN) Analyst Ratings
Bulls say
Exagen Inc has demonstrated strong financial performance, with its average selling prices (ASPs) increasing by 9% year-over-year to reach $441 per test, signaling positive pricing momentum. The company's revenue grew by 19% year-over-year over the past nine months, bolstered by balanced gains in ASPs and volumes, reflecting effective operational strategies and team leadership changes. Additionally, Exagen is strategically expanding its sales territories to 45 by the end of 2025, which is expected to further drive volume growth and enhance its revenue-generating capabilities.
Bears say
Exagen's financial outlook appears negative due to a lowered growth forecast for 2026, which is compounded by delays in achieving positive free cash flow and a decline in peer multiples. The company is facing challenges, including the loss of a direct bill account that contributed 2% to its volume, which has raised concerns about its growth trajectory and profitability timing. Additionally, the anticipated more muted average selling price (ASP) and gross margin expansion further exacerbate the company's revenue growth assumptions over the long term.
This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.
Exagen Inc (XGN) Analyst Forecast & Price Prediction
Start investing in Exagen Inc (XGN)
Order type
Buy in
Order amount
Est. shares
0 shares